glp receptor

1H-Benzimidazole-6-carboxylic acid is a GLP-1 receptor agonist.

GLP-1 receptor agonist 3 is a GLP-1 receptor agonist,Example 4A-1, has EC50s of 1.1 nM and 13 nM in Clone H6 and Clone C6 cell lines assay, respectively.

GLP-1 receptor agonist 4 is a glucagon-like peptide-1 receptor (GLP-1R) agonist with an EC50 of 64.5 nM, and is utilized in diabetes treatment research.

GLP-1 receptor agonist 2 is a glucagon-like peptide-1 receptor (GLP-1R) agonist.

GLP-1 Receptormodulator 1 (Compound 7) is an effective positive allosteric modulator of the GLP-1 receptor. It is utilized in the research of obesity and type 2 diabetes.

GLP-1 receptor agonist 15 (Example 4) is a GLP receptor agonist with an EC50 of 0.74 nM. It exhibits an IC50 of 10.1 μM against the hERG potassium ion channel. This compound is applicable for research in the diabetes field.

GLP-1 receptor agonist 7 is a potent glucagon-like peptide-1 (GLP-1) agonist, demonstrating research potential for GLP-1 related diseases, disorders, and conditions, including diabetes.

GLP-1 receptor agonist 8, a potent agonist of GLP-1 R, holds potential for diabetes, obesity, and nonalcoholic fatty liver disease (NAFLD) research[1].

GIP GLP-1 dual receptor agonist-1 (compound 4), a receptor agonist for both GIP and GLP-1, shows potential for researching metabolic disorders and fatty liver diseases, such as nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) [1].

Compound (S)-9, a GLP-1 receptor agonist, exhibits an EC50 of 76 nM for the glucagon GLP-1 receptor [1].

GLP-1 Receptor Agonist 10 (Compound 42), an agonist of the GLP receptor, reduces glucose excursions and inhibits food intake in mice. It is useful for research into type 2 diabetes (T2DM) and obesity [1].

GLP-1 Receptor Agonist 11 (compound 3) acts as an effective agonist for the GLP Receptor, finding use in research related to conditions like diabetes and non-alc. fatty liver disease [1].

Compound 20A, known as GLP-1 receptor agonist 12, acts as an agonist of the GLP receptor. It is utilized in researching diseases like diabetes [1].

GLP-1 Receptor Agonist 14 (compound 73) functions as a potent agonist of glucagon-like peptide-1 (GLP-1) and is pivotal in the management of diabetes and other metabolic disorders [1].

GLP-1 receptor agonist 9 citrate is an agonist of GLP-1.

GLP-1 receptoragonist 16 (Example 53) is a GLP-1 agonist applicable for research in diabetes, obesity, or diseases related to non-alcoholic steatohepatitis.

Semaglutide is a glucagon-like peptide 1 receptor (GLP-1R) agonist(EC50 of 6.2 pM in a reporter assay using BHK cells expressing the human receptor).

Semaglutide Acetate is an agonist of a glucagon-like peptide 1 (GLP-1) receptor and can be used in studies about the treatment of type 2 diabetes.

GLP-1R Agonist DMB is an agonist of glucagon-like peptide 1 receptor (GLP-1R; KB = 26.3 nM for the recombinant human receptor).

LSN3318839 is a potent and orally available glucagon-like peptide-1 receptor (GLP-1R) modulator.LSN3318839 enhances GLP-1R G-protein-coupled signaling and can be used to lower blood glucose.

Liraglutide (Liraglutida) is a synthetic analog of glucagon-like peptide-1 (GLP-1), an agonist of the GLP-1 receptor. Liraglutide can be used to treat type 2 diabetes and chronic obesity.

Tirzepatide (LY-3298176) is a dual agonist of glucose-dependent polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor with neuroprotective activity for the study of diabetes and obesity.

Tirzepatide sodium salt (LY3298176 sodium salt) is a GIP and GLP-1 receptor agonist with neuroprotective activity and can be used to treat obesity.

Avexitide (Exendin-3 (9-39) amide) (Exendin (9-39)) is a specific and competitive antagonist of glucagon-like peptide-1 (GLP-1) receptor.